Jean Hoffman‐Censits

14.9k total citations · 3 hit papers
153 papers, 3.4k citations indexed

About

Jean Hoffman‐Censits is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean Hoffman‐Censits has authored 153 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Surgery, 72 papers in Oncology and 48 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean Hoffman‐Censits's work include Bladder and Urothelial Cancer Treatments (117 papers), Urinary and Genital Oncology Studies (69 papers) and Cancer Immunotherapy and Biomarkers (49 papers). Jean Hoffman‐Censits is often cited by papers focused on Bladder and Urothelial Cancer Treatments (117 papers), Urinary and Genital Oncology Studies (69 papers) and Cancer Immunotherapy and Biomarkers (49 papers). Jean Hoffman‐Censits collaborates with scholars based in United States, Spain and Italy. Jean Hoffman‐Censits's co-authors include Elizabeth R. Plimack, David J. McConkey, Arlene O. Siefker‐Radtke, Woonyoung Choi, Sima P. Porten, Tiewei Cheng, Mai Tran, Tadeusz Majewski, Bogdan Czerniak and Beat Roth and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Cell and Cancer.

In The Last Decade

Jean Hoffman‐Censits

149 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

2014 1.2k citations Elizabeth R. Plimack, Jean Hoffman‐Censits et al. profile →
LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

2023 84 citations Thomas Powles, Begoña P. Valderrama et al. Annals of Oncology profile →
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline

2023 82 citations Jean Hoffman‐Censits et al. The Journal of Urology profile →

Peers

Countries citing papers authored by Jean Hoffman‐Censits

Since Specialization

Citations

This map shows the geographic impact of Jean Hoffman‐Censits's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Hoffman‐Censits with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Hoffman‐Censits more than expected).

Fields of papers citing papers by Jean Hoffman‐Censits

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Hoffman‐Censits. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Hoffman‐Censits. The network helps show where Jean Hoffman‐Censits may publish in the future.

Co-authorship network of co-authors of Jean Hoffman‐Censits

This figure shows the co-authorship network connecting the top 25 collaborators of Jean Hoffman‐Censits. A scholar is included among the top collaborators of Jean Hoffman‐Censits based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Hoffman‐Censits. Jean Hoffman‐Censits is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel Pretreatment Autoantibodies Correlate with Enfortumab Vedotin–Related Dermatologic Events in Patients with Advanced Urothelial Cancer 2025 ·Cancer Research Communications ·Evangelia Vlachou, Burles A. Johnson, David J. McConkey, Noah M. Hahn, Yuezhou Jing, Stephanie Russell, (unknown), Antony Rosen, Livia Casciola‐Rosen, Jean Hoffman‐Censits	0
2	Clinicopathologic and Prognostic Features of Sarcomatoid Urothelial Carcinoma 2025 ·The American Journal of Surgical Pathology ·Huili Li, Vamsi Parimi, Burles A. Johnson, (unknown), Ezra Baraban, Jean Hoffman‐Censits, Max Kates, David J. McConkey, Noah M. Hahn, Andrés Matoso	0
3	1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC) 2024 ·Annals of Oncology ·Thomas Powles, Michiel S. van der Heijden, Shilpa Gupta, Begoña P. Valderrama, (unknown), (unknown), Eiji Kikuchi, Jean Hoffman‐Censits, J.P. Maroto Rey, Christof Vulsteke, Gopa Iyer, Umang Swami, Sang Joon Shin, Alejo Rodríguez‐Vida, Michał Woźniak, Blanca Homet Moreno, Jie Lu, Changjun Yu, Leah J. Hogdal, Yohann Loriot	13
4	Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39. 2024 ·Journal of Clinical Oncology ·Michiel Simon Van Der Heijden, Shilpa Gupta, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Gopa Iyer, Yohann Loriot, Nancy A. Dawson, Jean Hoffman‐Censits, Nataliya Mar, Srikala S. Sridhar, (unknown), Sang Joon Shin, Evan Y. Yu, Ignacio Durán, (unknown), Xuesong Yu, Aditya Shetty, Abhishek Bavle, Thomas Powles	3
5	Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer 2024 ·American Society of Clinical Oncology Educational Book ·Evangelia Vlachou, Burles A. Johnson, Ezra Baraban, Rosa Nadal, Jean Hoffman‐Censits	4
6	Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1) 2024 ·Journal of Clinical Oncology ·Daniel M. Geynisman, Philip H. Abbosh, Eric A. Ross, Matthew R. Zibelman, Pooja Ghatalia, (unknown), James Ryan Mark, Lambros Stamatakis, Jean Hoffman‐Censits, Rosalia Viterbo, Richard E. Greenberg, Thomas M. Churilla, Eric M. Horwitz, M.A. Hallman, Marc C. Smaldone, Robert G. Uzzo, (unknown), Alexander Kutikov, Elizabeth R. Plimack	9
7	Enfortumab vedotin (EV) in cisplatin-eligible and ineligible patients with advanced urothelial cancer (aUC): A single-center experience. 2024 ·Journal of Clinical Oncology ·Evangelia Vlachou, Burles A. Johnson, Roy Elias, Noah M. Hahn, David J. McConkey, Jean Hoffman‐Censits	1
8	Exploration of enfortumab vedotin (EV)–related cutaneous events by race in two real-world cohorts. 2024 ·Journal of Clinical Oncology ·Evangelia Vlachou, Ronac Mamtani, Noah M. Hahn, Burles A. Johnson, Jean Hoffman‐Censits, (unknown)	1
9	Evaluating outcomes of sacituzumab govitecan (SG) in patients with urothelial cancer (UC), previously treated with enfortumab vedotin (EV). 2024 ·Journal of Clinical Oncology ·Evangelia Vlachou, Burles A. Johnson, Noah M. Hahn, (unknown), David J. McConkey, Jean Hoffman‐Censits	3
10	Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small‐cell carcinoma of the bladder 2023 ·Histopathology ·Vamsi Parimi, Woonyoung Choi, Mingxiao Feng, (unknown), Jean Hoffman‐Censits, Max Kates, Kara A. Lombardo, Éva Compérat, David J. McConkey, Noah M. Hahn, (unknown), Andrés Matoso	3
11	211MO EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) 2023 ·Annals of Oncology ·Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, (unknown), Sang Joon Shin, (unknown), Giuseppe Fornarini, (unknown), (unknown), Nataliya Mar, (unknown), Xin Yu, Seema Rao Gorla, Blanca Homet Moreno, Michiel S. van der Heijden	1
12	LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) breakdown → 2023 ·Annals of Oncology ·Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, (unknown), Sang Joon Shin, (unknown), Giuseppe Fornarini, (unknown), (unknown), Nataliya Mar, (unknown), Xin Yu, Seema Rao Gorla, (unknown)	84
13	Four versus 3 Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathological Response and Survival 2021 ·The Journal of Urology ·Hiten D. Patel, Sunil Patel, (unknown), (unknown), (unknown), (unknown), (unknown), Parth M. Patel, (unknown), Noah M. Hahn, Jean Hoffman‐Censits, Stephanie Berg, Trinity J. Bivalacqua, Max Kates, Marcus L. Quek	15
14	710P Comprehensive genomic profiling (CGP) of small cell neuroendocrine carcinoma of the bladder (NEBC) 2021 ·Annals of Oncology ·Andrea Necchi, Petros Grivas, Gennady Bratslavsky, Philippe E. Spiess, Sherri Z. Millis, Jean Hoffman‐Censits, Sumati Gupta, Brennan Decker, Natalie Danziger, Jeffrey S. Ross	1
15	Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience 2020 ·Clinical Genitourinary Cancer ·Jean Hoffman‐Censits, Woonyoung Choi, Trinity J. Bivalacqua, Philip M. Pierorazio, Max Kates, Kara A. Lombardo, (unknown), David J. McConkey, Edouard J. Trabulsi, Noah M. Hahn, Andrés Matoso	11
16	c15-162: Phase IB trial of radium 223 and niraparib in patients with castrate resistant prostate cancer (NiraRad). 2018 ·Journal of Clinical Oncology ·James Luke Godwin, Jean Hoffman‐Censits, Robert B. Den, Karen E. Knudsen, Matthew J. Schiewer, Benjamin E. Leiby, (unknown), Christine Hübert, Akash Patnaik, Guru Sonpavde, Oliver Sartor, Eddy S. Yang, William Kevin Kelly	1
17	Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study 2017 ·Annals of Oncology ·Andrea Necchi, Richard W. Joseph, Yohann Loriot, Jean Hoffman‐Censits, José Luis Perez‐Gracia, Daniel P. Petrylak, Christina Louise Derleth, Darren Tayama, Qingqing Zhu, Beiying Ding, Constanze Kaiser, Jonathan E. Rosenberg	214
18	Combination immunotherapy in genitourinary malignancies 2016 ·Current Opinion in Urology ·Jean Hoffman‐Censits, Lindsay Wilde	5
19	Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial 2016 ·Annals of Oncology ·Stephen J. O’Keefe, Jean Hoffman‐Censits, Roger B. Cohen, Ronac Mamtani, Daniel F. Heitjan, Scott Eliasof, Andrew B. Nixon, Barry Turnbull, Edward G. Garmey, (unknown), (unknown), (unknown), L. Jayaraman, Adrian M. Senderowicz, (unknown), (unknown), (unknown), David J. Vaughn, Amanda M. Smith, Naomi B. Haas	47
20	Chemotherapy for Penile and Urethral Carcinoma 2010 ·Urologic Clinics of North America ·Edouard J. Trabulsi, Jean Hoffman‐Censits	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact